Table 1.

Structure and receptor specificity of compounds under investigation

A. Compounds with 2-(benzimidazol-2-ylthio)-N-phenylacetamide scaffold [from [12]].
Compound	R1	R2	Specificity
AG-09/1	4-NO2	5-OMe	FPR1
AG-09/2	4-OEt	5-OMe	FPR1
AG-09/11	H	H	N.A.
AG-09/13	4-OMe	5-OEt	FPR1
AG-09/17	3,4-diOMe	5-OMe	FPR1/FPR2
AG-09/18	H	5-OMe	FPR1
AG-09/19	3-OMe	5-OMe	FPR1
AG-09/20	4-Cl	5-OMe	FPR1/FPR2
AG-09/21	4-Br	5-OMe	FPR1
AG-09/22	2-OMe	5-OMe	FPR1/FPR2
AG-09/25	3-Br	H	N.A.
AG-09/26	3-NO2, 4-Cl	4-Me	N.A.
AG-09/28	4-NO2	H	N.A.
AG-09/30	3-CF3	5-Me	N.A.

B. Compounds with N-phenethyl-N′-phenylurea scaffold [from [12]].
Compound	R1	R2	Specificity
AG-26	4-Cl	OMe	FPR2
AG-09/36	H	H	N.A.
AG-09/37	H	OMe	FPR2
AG-09/38	4-F	OMe	FPR2
AG-09/41	2,4-diCl	OMe	N.A.
AG-09/42	4-Br	OMe	FPR2
AG-09/45	4-F	Me	N.A.
AG-09/52	2-NO2	Cl	N.A.
AG-09/54	3-Me	Cl	N.A.

C. Compounds with piperazine scaffold [from [12]].
Compound	R1	R2	Specificity
AG-09/03	4-Br	4-F	FPR2
AG-09/04	4-Br	3-Cl	FPR2
AG-09/55	H	H	N.A.
AG-09/56	H	2-Cl	N.A.
AG-09/64	3-Cl,4-F	H	N.A.
AG-09/71	2-Br	H	N.A.
AG-09/72	3-Br	H	N.A.
AG-09/73	4-Br	H	FPR2
AG-09/74	4-Br	4-Cl	FPR2
AG-09/75	4-Br	3-Cl, 4-Me	FPR2
AG-09/76	4-Br	2-Me, 3-Cl	FPR2
AG-09/77	4-Br	2-Me, 5-Cl	FPR2
AG-09/82	4-Br	3-OMe	FPR2
AG-09/91			N.A.

D. Compounds with acetohydrazide scaffold [from [12]].
Compound	R1	R2	Specificity
AG-09/92	NO2		FPR2
AG-09/93	NO2		FPR2
AG-09/95	NO2		N.A.
AG-09/96	NO2		FPR2
AG-09/97	NO2		N.A.
AG-09/99	OMe		N.A.
AG-09/101			FPR2
AG-09/102			N.A.
AG-09/7			FPR2

E. Specific FPR2 agonists with 1-(2-indolylcarbonyl)-4-(1-benzimidazolyl)piperidine scaffolds [from [16]].
Compound	R	Specificity
F-5	Me	FPR2
F-6	Et	FPR2
F-7	iBu	FPR2
F-8	CF3	FPR2
F-9	Ph	FPR2

F. Specific FPR2 agonists with pyrazolone scaffold [from [9,31]].
Compound	R1	R2	Specificity
B-25	Me	4-Br	FPR2
B-35	Me	4-SMe	FPR2
B-42	Et	4-Cl	FPR2
B-43	iPro	4-Cl	FPR1/FPR2

G. Specific FPR2 agonists with 1-(2-indolylcarbonyl)-3-(1-benzimidazolyl)pyrrolidine and related scaffolds [from [16]].
Compound	R	X	Specificity
F-10	OMe	CH	FPR2
F-13	F	CH	FPR2
F-14	Cl	CH	FPR2
F-15	Br	CH	FPR2
F-16	OCF3	CH	FPR2
F-17	Et	CH	FPR2
F-18	OMe	N	FPR2

H. Compounds with 4-benzylpyridazin-3-one scaffold [from [17]].
Compound	R1	R2	Specificity
C-14a	3-OMe	NH-C6H4-Br (p)	FPR1/FPR2
C-14b	3-OMe	NH-C6H4-Br (m)	N.A.
C-14e	3-OMe	NH-C6H4-I (p)	FPR1/FPR2
C-14f	3-OMe	NH-C6H4-F (p)	FPR1
C-14h	3-OMe	NH-C6H4-CH3 (p)	FPR1/FPR2
C-14m	3-OMe		FPR1
C-14n	3-OMe	NH-C6H4-CF3 (p)	FPR1/FPR2
C-14r	3-OMe	N(CH3)-C6H4-Br (p)	N.A.
C-14x	4-OMe	NH-C6H4-Br (p)	FPR2
C-6c			N.A.

Compound	X	Specificity
C-17b	CH(CH3)CONH	FPR1
C-18a	CH2	N.A.
C-23	(CH2)2NH	N.A.

I. Structures of other FPR1/FPR2 agonists.
Compound	Structure	Specificity
AG-14		FPR111
AG-22		FPR1/FPR212
AG-09/5		FPR212
AG-09/6		FPR212
AG-09/8		FPR212
AG-09/9		FPR1/FPR212
AG-09/10		FPR1/FPR212
Quin-C1		FPR27
S-1		FPR211
S-2		FPR211
1910-5441		FPR18 (activity for FPR2 is unknown)
fMLF		FPR1/FPR217
WKYMVm		FPR1/FPR217